BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
- Conditions
- Pleural Mesothelioma Malignant Advanced
- Interventions
- Registration Number
- NCT03762018
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Brief Summary
The aim of this clinical trial is to assess the effect of treatment with a monoclonal antibody called atezolizumab in patients diagnosed with a type of lung cancer called malignant pleural mesothelioma. The efficacy (whether the treatment works), safety and tolerability (side effects of treatment) of atezolizumab plus bevacizumab in combination with standard chemotherapy versus bevacizumab in combination with standard chemotherapy will be investigated.
- Detailed Description
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer arising from the mesothelial surface of the pleura. In Europe, the incidence is about 20 per million and is almost always caused by asbestos exposure, with a usual lag time of 30 years between exposure and presentation. Patients diagnosed with advanced MPM have limited treatment options, representing a strict unmet need. Despite decades of clinical research, cytotoxic chemotherapy remains one of the few therapeutic options that has been proven to improve survival in advanced MPM in a randomised controlled trial.
The combination of cisplatin and pemetrexed has become standard first-line therapy worldwide for patients who are not suitable for aggressive surgery or in whom chemotherapy is recommended as part of a multimodality regimen. Carboplatin is often substituted for cisplatin, due to simpler and shorter administration and assumption of a more favourable toxicity profile based on experience in other diseases. Patients with MPM have limited treatment options, representing a strict unmet need.
An antibody is a common type of protein usually made in the body in response to a foreign substance. Antibodies attack foreign substances and protect against infection. The two monoclonal antibodies (atezolizumab and bevacizumab) used in this trial are laboratory-produced antibodies. Atezolizumab is engineered to attach to immune cells to stimulate their activity against cancer cells.
Atezolizumab and bevacizumab are both approved by the European Medicines Agency for the treatment of lung and other cancers. The addition of atezolizumab to bevacizumab plus standard chemotherapy for the treatment of MPM is being investigated in this trial.
All participants will receive 4-6 cycles of standard chemotherapy consisting of carboplatin AUC 5 (area under the plasma concentration versus time curve) plus pemetrexed 500mg/m\^2 given intravenously, on day 1 of every 3 week cycle for about 12 to 18 weeks.
Participants will be randomly assigned to one of two treatment groups:
Treatment 1
* Bevacizumab 15 mg/kg intravenously on day 1 of every 3-week cycle, plus
* 4-6 cycles of chemotherapy
OR
Treatment 2
* Atezolizumab 1200 mg fixed dose intravenously on day 1 of every 3-week cycle, plus
* Bevacizumab 15 mg/kg, intravenously on day 1 of every 3-week cycle, plus
* 4-6 cycles of chemotherapy
Participants will continue to receive treatment until disease progression, or until treatment is stopped at the request of the participant or treating doctor, or the participant withdraws consent.
A total of 400 participants from approximately 45 centres in Europe are expected to be included in this trial which will take approximately 6 years to be completed after the first participant is enrolled.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 401
- Histologically confirmed advanced malignant pleural mesothelioma (all histological subtypes are eligible)
- Not amenable for radical surgery based on local standards
- Evaluable disease or measurable disease as assessed according to the modified response evaluation criteria for solid tumours for mesothelioma (mRECIST) v1.1
- Availability of tumour tissue for translational research
- Age >18 years
- Performance Status 0-1
- Life expectancy >3 months
- Adequate haematological, renal and liver function
- Completed baseline quality of life (QoL) questionnaire
- Women of childbearing potential and sexually active men must agree to use highly effective contraception
- Able to understand and give written informed consent and comply with trial procedures
- Prior treatment for malignant pleural mesothelioma. Prior radiotherapy for symptom control is allowed, but the irradiated lesion cannot be used as target lesion. If the patient has another target lesion, the patient is eligible.
- Treatment with systemic immune-stimulatory agents within 4 weeks or five half-lives of the drug prior to randomisation and during protocol treatment.
- Treatment with systemic immunosuppressive medications within 2 weeks prior to randomisation and during protocol treatment.
- Previous allogeneic tissue/solid organ transplant
- Live vaccines within 4 weeks prior to first dose of protocol treatment
- Inadequately controlled hypertension
- Prior history of hypertensive crisis or hypertensive encephalopathy
- Significant vascular disease within 6 months prior to randomisation
- History of haemoptysis
- Evidence of bleeding diathesis or coagulopathy
- Active autoimmune disease that has required systemic treatment in past 2 years
- History of active diverticulitis
- Previous treatment with atezolizumab and/or bevacizumab or parallel participation in other interventional clinical trial with atezolizumab and/or bevacizumab.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Bevacizumab plus chemotherapy Carboplatin Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks Bevacizumab plus chemotherapy Pemetrexed Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks Bevacizumab plus chemotherapy Bevacizumab Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks Atezolizumab plus bevacizumab plus chemotherapy Pemetrexed Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks Atezolizumab plus bevacizumab plus chemotherapy Bevacizumab Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks Atezolizumab plus bevacizumab plus chemotherapy Carboplatin Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks Atezolizumab plus bevacizumab plus chemotherapy Atezolizumab Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks
- Primary Outcome Measures
Name Time Method Overall Survival (OS) From date of randomisation until death from any cause, assessed up to 58 months Overall survival is defined as the time from the date of randomisation until death from any cause. Data for patients who are not reported as having died at the date of analysis will be censored at the date when they were last known to be alive. Data for patients without post-baseline information will be censored at the date of randomization (plus 1 day).
- Secondary Outcome Measures
Name Time Method Objective Response Rate (ORR) From start of protocol treatment acorss all time-points until end of protocol treatment or, as an alternative approach, until the end of follow-up, assessed up to 58 months Defined as the percentage of patients that achieve a best overall response \[complete response (CR) or partial response (PR)\] evaluated according to the mRECIST v1.1 across all post-randomization time-points until the end of protocol treatment or, as an alternative approach, until the end of follow-up. Confirmation of response will not be required.
Progression-free Survival (PFS) according to the mRECIST v1.1 From date of randomisation until documented progression or death, if progression is not documented, assessed up to 58 months PFS is defined as the time from the date of randomisation until documented progression (according to the mRECIST v1.1) or death, if progression is not documented. Censoring (for participants without a PFS/death event) will occur at the date of last tumour assessment. Patients without a post-baseline tumour assessment will be censored at the date of randomization (plus 1 day).
Disease Control (DC) at 24 weeks 24 weeks after protocol treatment start Defined as complete or partial response, or disease stabilisation at 24 weeks.
Number of participants with treatment related adverse events according to Common Toxicity Criteria for Adverse Events (CTCAE) v5.0 Assessed from the date of informed consent until 90 days after protocol treatment discontinuation. Analysed at 58 months after randomisation of the first patient Assessed through analysis of the worst grade of toxicity/adverse events and will include all participants who received at least one dose of protocol treatment. Adverse events leading to dose interruption, withdrawal of protocol treatment and deaths, laboratory parameters and abnormalities and vital signs over the whole treatment period will be assessed and graded according to CTCAE v5.0 criteria.
Time to Treatment Failure (TTF) From randomisation until discontinuation of protocol treatment for any reason, assessed up to 58 months Defined as the time from the date of randomisation to discontinuation of protocol treatment for any reason (including progression of disease, death, discontinuation of at least one of the drugs consisting the treatment combination due to any reason, such as toxicity or refusal). Censoring will occur at the last follow-up date.
Duration of Response (DoR) From date of first documentation of objective response until date of first documented progression/ relapse or death, assessed up to 58 months Defined as the interval from the date of first documentation of objective response (complete response or partial response, according to the mRECIST v1.1) to the date of first documented progression/ relapse or death.
Trial Locations
- Locations (42)
CHU Liege
🇧🇪Liege, Belgium
Le Mans - CHG
🇫🇷Le Mans, France
Kantonsspital Aarau
🇨🇭Aarau, Switzerland
Tours - CHU
🇫🇷Tours, France
Instituto Europeo di Oncologia (IEO)
🇮🇹Milan, Italy
Kantonsspital Graubünden
🇨🇭Chur, Switzerland
Curie Cancer Center Paris
🇫🇷Paris, France
Lyon - Centre Léon Bérard
🇫🇷Lyon, France
IRCCS Instituto Tumori Giovanni Paolo II
🇮🇹Bari, Italy
Kantonsspital Winterthur
🇨🇭Winterthur, Switzerland
Caen- CHU
🇫🇷Caen, France
Unicancer - Institut Bergonie
🇫🇷Bordeaux, France
University Hospital Leuven
🇧🇪Leuven, Belgium
Toulouse - CHU
🇫🇷Toulouse, France
Hospital Nord
🇫🇷Marseille, France
SS Antonio e Biagio e Cesare Arrigo Hospital
🇮🇹Alessandria, Italy
AULSS2 Marca Trevigiana Treviso
🇮🇹Treviso, Italy
ICO Hospitalet
🇪🇸Barcelona, Spain
Alicante University Hospital ISABIAL
🇪🇸Alicante, Spain
University Hospital of Turin
🇮🇹Turin, Italy
Fondazione IRCCS Istituto Nazionale die Tumori
🇮🇹Milan, Italy
Vall Hebron University Hospital/Vall Hebron Institue Oncology
🇪🇸Barcelona, Spain
Puerta de Hierro Hospital
🇪🇸Majadahonda, Spain
Virgen del Rocio
🇪🇸Seville, Spain
Hospital Parc Tauli Sabadell
🇪🇸Sabadell, Spain
Complexo Hospitalario Universitario de Vigo
🇪🇸Vigo, Spain
Ferdinando Cerciello
🇨🇭Bern, Switzerland
Istituto Oncologica della Svizzera Italiana
🇨🇭Bellinzona, Switzerland
Luzerner Kantonsspital
🇨🇭Lucerne, Switzerland
CHUV
🇨🇭Lausanne, Switzerland
Kantonsspital St. Gallen
🇨🇭Saint Gallen, Switzerland
UniversitätSpital Zürich
🇨🇭Zürich, Switzerland
Addenbrooke's Hospital
🇬🇧Cambridge, United Kingdom
Clatterbridge Cancer Centre
🇬🇧Liverpool, United Kingdom
Guy's and St Thomas' Hospital
🇬🇧London, United Kingdom
Royal Marsden Hospital (Sutton)
🇬🇧London, United Kingdom
Royal Marsden Hospital (Fulham Road)
🇬🇧London, United Kingdom
Wythenshawe Hospital
🇬🇧Manchester, United Kingdom
Kent Oncology Centre
🇬🇧Maidstone, United Kingdom
Plymouth Hospitals NHS Trust
🇬🇧Plymouth, United Kingdom
Weston Park Hospital
🇬🇧Sheffield, United Kingdom
Royal Cornwall Hospital
🇬🇧Truro, United Kingdom